Invitrogen has introduced two new RNAi research vectors.
The first, Block-iT HiPerform Lentiviral Pol-II miR RNAi expression system with Emerald Green Fluorescent Protein, can be used to deliver to non-dividing, primary, and hard-to-transfect cells, Invitrogen said.
The second, Block-iT Inducible Pol-II miR RNAi expression system, uses a tetracycline-inducible promoter that allows researchers to control RNAi expression.
Altogen Biosystems has introduced new contract research services for RNAi including transfection services, assay development and library screening, cloning and vector construction, stable cell-line generation, and RNAi and gene-targeting experiments.
Thermo Fisher Scientific has introduced the Dharmacon Accell siRNA, a novel form of siRNA that is absorbed directly by cells without the use of conventional delivery methods such as transfection reagents, viruses, or electroporation.
According to the company, the siRNA can silence genes in all cell types tested to date when mixed with the optimized Accell delivery media and added to cultured cells.